ATHE vs. AGRX, GLS, PULM, CNTX, HILS, GLMD, CING, ADIL, ERNA, and MRKR
Should you be buying Alterity Therapeutics stock or one of its competitors? The main competitors of Alterity Therapeutics include Agile Therapeutics (AGRX), Gelesis (GLS), Pulmatrix (PULM), Context Therapeutics (CNTX), Hillstream BioPharma (HILS), Galmed Pharmaceuticals (GLMD), Cingulate (CING), Adial Pharmaceuticals (ADIL), Eterna Therapeutics (ERNA), and Marker Therapeutics (MRKR). These companies are all part of the "pharmaceutical preparations" industry.
Alterity Therapeutics vs.
Agile Therapeutics (NASDAQ:AGRX) and Alterity Therapeutics (NASDAQ:ATHE) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, risk, community ranking, earnings, profitability, valuation, dividends and institutional ownership.
Agile Therapeutics has a beta of 1.13, indicating that its stock price is 13% more volatile than the S&P 500. Comparatively, Alterity Therapeutics has a beta of 1.26, indicating that its stock price is 26% more volatile than the S&P 500.
5.7% of Agile Therapeutics shares are held by institutional investors. Comparatively, 1.7% of Alterity Therapeutics shares are held by institutional investors. 0.5% of Agile Therapeutics shares are held by company insiders. Comparatively, 38.8% of Alterity Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Alterity Therapeutics has a consensus target price of $25.00, suggesting a potential upside of 823.36%. Given Alterity Therapeutics' higher possible upside, analysts plainly believe Alterity Therapeutics is more favorable than Agile Therapeutics.
Alterity Therapeutics has a net margin of 0.00% compared to Agile Therapeutics' net margin of -797.48%. Alterity Therapeutics' return on equity of 0.00% beat Agile Therapeutics' return on equity.
Agile Therapeutics received 420 more outperform votes than Alterity Therapeutics when rated by MarketBeat users. Likewise, 69.87% of users gave Agile Therapeutics an outperform vote while only 66.67% of users gave Alterity Therapeutics an outperform vote.
Alterity Therapeutics has lower revenue, but higher earnings than Agile Therapeutics.
In the previous week, Agile Therapeutics had 5 more articles in the media than Alterity Therapeutics. MarketBeat recorded 6 mentions for Agile Therapeutics and 1 mentions for Alterity Therapeutics. Agile Therapeutics' average media sentiment score of -1.00 equaled Alterity Therapeutics' average media sentiment score.
Summary
Alterity Therapeutics beats Agile Therapeutics on 8 of the 14 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ATHE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Alterity Therapeutics Competitors List
